BiotechTube
InkVivo

InkVivo

Lausanne, Switzerland· Est.
inkvivo.tech
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

InkVivo Technologies is a 2020-founded, ETH Zurich spin-off based in Lausanne, Switzerland, focused on advanced drug delivery. The company has developed a proprietary, scalable polymer platform designed for the reformulation of existing drugs to enhance bioavailability, reduce dosing frequency, and minimize side effects. Having secured CHF 1.1M in pre-seed funding, InkVivo is advancing a lead anemia treatment and exploring partnerships while preparing for a US roadshow in 2025. Its business model centers on partnering with pharma companies to create new IP and extend product lifecycles through improved formulations.

Anemia

Technology Platform

Proprietary polymer-based platform for controlled, localized, and sustained release of active ingredients (small molecules to biologics) across oral (GARDS) and injectable (SHEALD) routes. Built on FDA-approved/GRAS materials, it enables tunable drug release and rapid reformulation.

Opportunities

The platform enables high-value lifecycle management for drugs nearing patent expiry and can rescue compounds with poor bioavailability.
Leveraging expedited regulatory pathways like FDA 505(b)(2) offers partners a faster, lower-cost development route.
The ability to deliver biologics and target unmet needs in oral delivery presents significant expansion potential.

Risk Factors

The company is pre-revenue and reliant on near-term partnership deals and follow-on financing.
Its platform technology must be successfully validated across multiple drug classes and in human trials to attract major pharma partners.
It operates in a highly competitive drug delivery landscape with numerous established and startup competitors.

Competitive Landscape

InkVivo competes in the crowded drug delivery sector against large established players (e.g., Lonza, Catalent) and numerous startups specializing in polymers, lipids, or other delivery technologies. Its differentiation lies in the claimed versatility of its single polymer platform for both oral and injectable routes and its focus on rapid reformulation for lifecycle management. Success will depend on demonstrating superior performance and forging strong pharma alliances.

More companies in Drug Delivery & Formulation →More companies in Switzerland →